Cellular and Molecular Life Sciences

, Volume 71, Issue 3, pp 365–378

Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia

  • Noa Tal
  • Chen Shochat
  • Ifat Geron
  • Dani Bercovich
  • Shai Izraeli
Review

DOI: 10.1007/s00018-013-1337-x

Cite this article as:
Tal, N., Shochat, C., Geron, I. et al. Cell. Mol. Life Sci. (2014) 71: 365. doi:10.1007/s00018-013-1337-x

Abstract

Cancer is often caused by deregulation of normal developmental processes. Here, we review recent research on the aberrant activation of two hematopoietic cytokine receptors in acute lymphoid leukemias. Somatic events in the genes for thymic stromal lymphopoietin and Interleukin 7 receptors as well as in their downstream JAK kinases result in constitutive ligand-independent activation of survival and proliferation in B and T lymphoid precursors. Drugs targeting these receptors or the signaling pathways might provide effective therapies of these leukemias.

Keywords

Thymic stromal lymphopoietin CRLF2 IL7 receptor alpha JAK1 JAK2 Leukemia 

Copyright information

© Springer Basel 2013

Authors and Affiliations

  • Noa Tal
    • 1
    • 2
  • Chen Shochat
    • 2
    • 3
    • 4
  • Ifat Geron
    • 1
    • 2
    • 5
  • Dani Bercovich
    • 3
    • 4
  • Shai Izraeli
    • 1
    • 2
  1. 1.Cancer Research Center, Sheba Medical CenterEdmond and Lily Safra Children’s HospitalRamat GanIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Migal Galilee Technology CenterKiryat ShmonaIsrael
  4. 4.Tel Hai CollegeUpper GalileeIsrael
  5. 5.Division of Biological Sciences and Department of Medicine Stem Cell ProgramUniversity of California San DiegoLa JollaUSA

Personalised recommendations